The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Express Scripts to add Zepbound to National Preferred Formulary
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
This product will be manufactured at Lupin’s Pithampur facility in India
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Subscribe To Our Newsletter & Stay Updated
